HOME >> MEDICINE >> NEWS
Experimental pill found to improve symptoms in patients with non-small-cell lung cancer

ORLANDO, FLA. (May 19, 2002, 12:00 p.m., EST) An experimental pill has been found to improve symptoms and quality of life in patients with non-small-cell lung cancer, according to research findings presented by Ronald B. Natale, M.D., Acting Medical Director at Cedars-Sinai Comprehensive Cancer Center, and lead author of the study. The pill, called ZD 1839 (Iressa) is one of a new class of drugs that targets and blocks a key growth signal in cancer cells.

The study, presented at the 38th annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, evaluated 216 patients with recurrent non-small-cell lung cancer who had undergone two or more rounds of chemotherapy. One group of patients received 250 mg of ZD 1839 (Iressa) daily, while the second group received ZD 1839 at 500 mg each day until the disease progressed. The investigators found that lung cancer symptoms, such as cough, shortness of breath, chest pain or tightness, appetite and fatigue, were greatly improved in about 40 percent of patients. Further, they found that symptom improvement was associated with a longer survival.

Our results show that patients who felt better after taking ZD 1839, actually lived longer than those whose symptoms did not improve, said Dr. Natale. This is important because it shows that a daily pill reduced symptoms such to the extent that many of our patients were able to resume their normal activities and enjoy life for longer.

ZD 1839 (Iressa), a pill developed by AstraZeneca, has been found to work in both laboratory and clinical trials by targeting and blocking a key growth signaling mechanism in cancer cells called the epidermal growth factor receptor (EGFR). Otherwise known as HER1, the EGFR is a part of the HER kinase family of proteins that control cell growth and can stimulate the spread of cancer when over-expressed on malignant cells.

Non-small-cell lung cancer is the most common type of lung cancer,
'"/>

Contact: Kelli Stauning
kelli.stauning@cshs.org
310-423-3674
Cedars-Sinai Medical Center
19-May-2002


Page: 1 2 3

Related medicine news :

1. St. Jude scientist wins International Society of Experimental Hematology award
2. Experimental drug improves sleep in older patients, Wake Forest Baptist study shows
3. Experimental drug used to treat recurrent ovarian cancer shows promising results
4. Experimental treatment yields new hope for children battling cerebral palsy
5. Experimental drugs show promise in halting brain tumors
6. Experimental drugs reduce neuron death in rats following insulin shock
7. Experimental drug reverses effects of Fabry disease in mice
8. Experimental peptides prevent diabetes and halt its progression
9. Experimental testosterone patch shows promise for treating diminished sexual function in surgically menopausal women
10. Clinical Trial Demonstrates Experimental Growth Factor Increases Eligibility For Autologous Stem Cell Transplantation
11. Acupuncture found to lower elevations in blood pressure

Post Your Comments:
(Date:7/30/2014)... 2014. A new network of 25 regional stroke centers ... (NIH StrokeNet) is working to change the way ... advances of the last two decades, stroke remains a ... or disability for 795,000 Americans. The numbers are expected ... , To accelerate the pace of progress, NIH ...
(Date:7/30/2014)... OR (PRWEB) July 30, 2014 LTC Consumer, ... evaluate long term care insurance, features an Instant Quote tool ... Director and co-founder of LTC Consumer. Quotes are free and ... a click in only seven areas – including age, gender, ... on screen within seconds (you don’t need to enter any ...
(Date:7/30/2014)... The Institute for Integrative Nutrition (IIN), ... Arianna Huffington has joined as a guest speaker and is ... Training Program . , Arianna Huffington is the chair, president, ... blogging site that won a Pulitzer Prize in 2012 for ... was included on the Forbes “Most Powerful Women” list of ...
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- For patients with ... enough to trigger airway inflammation for at least 24 ... what you smell, but also what you think you ... Chemical Senses Center in Philadelphia, said in a Monell ... scents and fragrances. When we expect that an odor ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 According ... and Machine Vision Market by Technology (ICS, MES, ... Embedded), Components (Camera, FGOL), Application (Process, Discrete) - ... published by MarketsandMarkets, the Mexican market is expected ... 6.18% by 2020. , Browse 70 market data ...
Breaking Medicine News(10 mins):Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 3Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 4
(Date:7/30/2014)... 30, 2014   Epic Sciences, Inc. ... and develops novel diagnostics to personalize and advance ... the completion of a $30 million Series C ... RusnanoMedInvest (RMI) and Arcus Ventures, existing investors Domain ... as well as undisclosed individual investors. With the ...
(Date:7/30/2014)... 2014 Die Apex Medical Corporation ... Bereich Atemtherapie- und Druckzonenprodukte, gibt bekannt, dass ... Deutschland anfechten werden. Dieses hat entschieden, dass ... von ResMed verletze. Apex weist darauf hin, ... verschiedene Patente von ResMed Anfechtungen wegen Nichtigkeit ...
(Date:7/29/2014)... Amgen (NASDAQ: AMGN ) today announced financial ... include: , Total revenues increased 11 percent to ... by strong performance across the portfolio, particularly Enbrel ® ... (denosumab) and XGEVA ® (denosumab). , Adjusted ... revenues and a significant increase in the profitability of ...
Breaking Medicine Technology:Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
Cached News: